Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Pumitamig combined with chemotherapy compared to Nivolumab combined with chemotherapy in people who have not received prior treatment for advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. This phase 23 randomized study aims to better understand treatment options for these types of cancer. Participants will receive specified doses of Pumitamig or Nivolumab along with chemotherapy drugs such as Folfox or Capox on scheduled days. The study includes multiple experimental treatment arms and uses a double-blind method to compare these combinations. Treatment and evaluations will continue for up to several years, including a primary outcome measurement period lasting up to 2 to almost 4 years. Throughout the study, participants will undergo regular assessments to monitor tumor response, progression-free survival, overall survival, and other cancer control measures using standardized criteria like RECIST v1.1. These evaluations include investigator assessments and blinded independent reviews. Safety and dosing recommendations will also be closely monitored. Participants may expect frequent visits and follow-ups over the course of the study, which lasts several years from enrollment to outcome measurement.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SAR445399, a drug administered by injection, in adults with moderate to severe hidradenitis suppurativa. This multinational, randomized, double-blind, placebo-controlled Phase 2 study aims to compare two different doses of SAR445399 with a placebo to find the best dose for treating this condition. Participants will be randomly assigned to receive one of two SAR445399 dose regimens or a matching placebo. The treatment period lasts 32 weeks, including a 16-week initial double-blind phase followed by a 16-week treatment-blinded extension period. The total study duration for each participant is up to 46 weeks, with a total of 16 study visits scheduled throughout this time. During the study, participants will be monitored through various assessments including clinical response measures such as Hidradenitis Suppurativa Clinical Response HiSCR levels, severity scoring, skin pain ratings, quality of life questionnaires, laboratory tests, vital signs, and electrocardiograms. Researchers will also track drug concentrations and immune responses. Safety will be closely monitored throughout the study and extension period to evaluate any adverse events or significant changes in health.
Actively Recruiting
Researchers are investigating autoinflammatory diseases AID, which involve recurring inflammatory episodes without infection, cancer, or adaptive immune system problems. This study focuses on both monogenic hereditary periodic syndromes and polygenic or multifactorial AID, including rare conditions like Behets disease, Still disease, Schnitzlers disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, among others. The goal is to gather detailed data to improve understanding and management of these rare diseases through an international collaboration. The study uses the AIDA registry, a secure online platform for collecting demographic, genetic, clinical, laboratory, radiologic, and therapeutic information. Data are gathered retrospectively and prospectively during routine clinical visits scheduled every 3-6 months. Eleven registries focus on different AID conditions, enabling comprehensive data collection to identify clinical patterns, treatment impacts, and long-term outcomes over a period of at least 10 years. Participants provide information during their usual care visits, allowing researchers to track changes in disease activity, organ involvement, inflammatory markers, visual function, pain levels, fatigue, fertility, and socioeconomic factors. The study monitors these outcomes over multiple timepoints up to 120 months. Data privacy is ensured by pseudonymizing patient information. This registry supports multiple clinical studies and aims to enhance knowledge, awareness, and future research on autoinflammatory diseases worldwide.
Actively Recruiting
Researchers are evaluating the use of Socratic questioning as a new approach to help adults aged 18 to 65 with obesity lose weight in a primary care setting. This pilot trial aims to determine if this questioning method can lead to greater weight loss compared to regular care. The study is a pragmatic randomized controlled trial led by S31d31ka Ece Yokuf, focusing on effective weight management strategies for patients with obesity. Participants will be divided into two groups one receiving counseling using the Socratic questioning technique during follow-up visits, and the other receiving routine obesity care from their physicians. The intervention group will have face-to-face sessions on days 0, 15, 30, and 60, each lasting about 10-15 minutes, where physicians will use a checklist and record notes with an obesity diagnosis code. The control group will receive standard care which may include nutritional and lifestyle advice but not Socratic questioning. Both groups will have measurements taken at specified visits over a 3-month period. During the study, participants will complete baseline and final questionnaires including demographic information and the Hospital Anxiety and Depression Scale. They will attend five in-person visits over three months, where weight, height, and waist circumference will be measured. Physicians will provide brief counseling at each visit and record data in the health information system. The main outcome measured is the change in body weight after 3 months, along with secondary outcomes like BMI and waist circumference changes. Safety monitoring includes referral to mental health services if needed. The total participation duration is about 3 months.
Actively Recruiting
Researchers are evaluating how well the Turkish Ministry of Healths three-level color-coded triage system Red, Yellow, Green predicts serious clinical outcomes in children aged 0 to 18 years who come to pediatric emergency departments with fever. This observational study also examines whether specific vital signs taken at triage, such as heart rate, respiratory rate, oxygen levels, capillary refill time, consciousness level, and overall appearance, add useful information beyond the triage category. The study involves multiple centers across Turkey and aims to better understand early indicators of serious illness in febrile children. Children presenting with a fever of 38.0C or higher at triage, or with a history of recent fever, are enrolled consecutively over a 3-month period at ten pediatric emergency departments. Each child receives routine triage using the Ministry of Healths system, and physiological data are recorded on a standardized form without influencing clinical decisions. The study does not alter usual care or triage, focusing instead on observing and analyzing data already collected during routine visits. Participants undergo standard triage assessments and their clinical outcomes are monitored for up to 30 days, including serious events like hospital admission, sepsis protocol activation, intravenous treatments, and re-attendance with admission. Researchers collect and analyze this data to evaluate triage accuracy and the added value of vital signs in predicting outcomes. The total participation period for each child corresponds to their emergency visit and follow-up within 30 days, with no additional interventions or changes to usual care.